A retrospective cohort study to compare treatment persistence and dose intensification as indicators of real-world effectiveness in patients with Crohn's disease receiving Ustekinumab or vedolizumab
Latest Information Update: 07 Dec 2020
At a glance
- Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 07 Dec 2020 New trial record
- 28 Oct 2020 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week